Both CBAM Director Dr. Steve Shoptaw and  UCLA’s Dr. Raphael Landovitz delivered well-received plenaries at the HIV Prevention Trials Network annual meeting in Washington DC on June 16. Dr. Shoptaw presented early in the order with a brief but comprehensive presentation on the topic of “Non-Injection Substance Use and HIV.” Dr. Landovitz closed out the afternoon of science with a tremendous presentation on “PrEP: Promising New Agents”.

Dr. Shoptaw is working with his colleagues in leadership at HPTN to bring focused attention to the contributions to the HIV epidemic made by people who use non-injection substances, including binge drinking. Dr. Landovitz is the Protocol Team Leader for HPTN 083, A Phase 2b/3 Double Blind Efficacy Study Of Quarterly Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil.

Congrats to them both for representing UCLA.


CBAM is a multidisciplinary center that seeks to advance the prevention and treatment of chronic illnesses, especially in communities with health disparities. As part of the UCLA Department of Family Medicine, CBAM works at the intersection of academia and community with a focus on treating addictions and preventing the spread of HIV.

© The UCLA Center for Behavioral & Addiction Medicine (CBAM). All Rights Reserved.